期刊文献+

新型抗精神病药物的研究进展 被引量:9

Recent research advances on novel antipsychotics
下载PDF
导出
摘要 对近年来新型抗精神病药物按化学结构进行分类,并对部分药物的构效关系、药理活性等进行分析总结。指出新型抗精神病药物的化学结构和作用机制不同于已有的抗精神病药物,具有疗效好、不良反应小等优点,有望为精神分裂症的治疗开创新的局面。 Novel antipsychotics classified by structures are introduced in this paper, and their structure-activity relationships and pharmacology are analyzed and summarized. Different from known antipsychotics in structures and mechanism of action, novel antipsychotics with good potency and less side effects will start a new era in the field of antipsychotics.
作者 张刚 陈玉彬
出处 《中国药物化学杂志》 CAS CSCD 2007年第3期188-192,共5页 Chinese Journal of Medicinal Chemistry
关键词 新型抗精神病药 构效关系 作用机制 精神分裂症 novel antipsychotics SAR action mechanism schizophrenia
  • 相关文献

参考文献23

  • 1周启霆,金国章,陈丽娟.左、右旋氯斯库利啉及它们的用途:中国,1115318[P].1999-10-06.
  • 2李剑锋,索瑾,夏广新,等.左旋卤代斯库利啉盐及其制备方法和用途:中国,1603324A[P].2005-04-06.
  • 3LI Jian-feng,JIN Guo-zhang,SHEN Jing-shan,et al.1-Chloroscoulerine mesylate[ J ].Drugs Fut,2006,31(5):379-384.
  • 4LANGE H M,Jos,COOLEN H K A C,van STUIVENBERG H H,et al.Synthesis,biological properties,and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB1 cannabinoid receptor antagonists[J].J Med Chem,2004,47(3):627-643.
  • 5WAGNER J A,JARAI Z,BATKAI S,et al.Hemodynamic effects of cannabinoids:coronary and cerebral vasodilation mediated by cannabinoid CB1 receptors[J].Eur J Pharmacol,2001,423(2/3):203-210.
  • 6RAWLS S M,CABASSA J,GELLER E B,et al.CB1 receptors in the preoptic anterior hypothalamus regulate WIN 55212--2-[4,5-dihydro-2-methyl-4-(4-morpholinylmethyl) ] -1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[ 3,2,1 ] quinolin-6-one-induced hypothermia[J].J Pharmacol Exp Ther,2002,301(3):963 -968.
  • 7LANGE J H M,KRUSE C G,TIPKER J,et al.4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity:WO,2002/076949 A1[P].2002-03-10.
  • 8ORTIZ A.Pyrazole derivatives for the treatment of psychiatric disorders:WO,2006/060201 A2[ P ].2006-08-06.
  • 9TUINSTRA T,HERREMANS A H J,van der HEYDEN J A M,et al.SLV310,a molecule combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition,active in preclinical models for antipsychotic as well as anxiolytic activity[J].Eur Neuropsychopharmacol,2001,11(Suppl.3):S251.
  • 10GOFF D C,MIDHA K K,SARID-SEGAL O,et al.A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia[ J ].Psychopharmacology(Berl),1995,117(4):417-423.

同被引文献77

引证文献9

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部